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DObjectives: The Cox maze III procedure achieved high cure rates and became the surgical gold standard for the
treatment of atrial fibrillation. Because of its invasiveness, a more simplified ablation-assisted procedure, the
Cox maze IV procedure, has been performed at our institution since January 2002. The study examined multiple
preoperative and perioperative variables to determine predictors of late recurrence.
Methods: Data were collected prospectively on 282 patients who underwent the Cox maze IV procedure from
January 2002 through December 2009. Forty-two percent of patients had paroxysmal and 58% had either
persistent or long-standing persistent atrial fibrillation. All patients were available for follow-up. Follow-up in-
cluded electrocardiograms in all patients. Since 2006, 24-hour Holter monitoring was obtained in 94% of
patients at 3, 6, and 12 months. Data were analyzed by means of logistic regression analysis at 12 months,
with 13 preoperative and perioperative variables used as covariates.
Results: Sixty-six percent of patients had a concomitant procedure. After an ablation-assisted Cox maze pro-
cedure, the freedom from atrial fibrillation was 89%, 93%, and 89% at 3, 6, and 12 months, respectively.
The freedom from both atrial fibrillation and antiarrhythmic drugs was 63%, 79%, and 78% at 3, 6, and 12
months, respectively. The risk factors for atrial fibrillation recurrence at 1 year were enlarged left atrial diameter
(P ¼ .027), failure to isolate the entire posterior left atrium (P ¼ .022), and early atrial tachyarrhythmias
(P ¼ .010).
Conclusions: The Cox maze IV procedure has a high success rate at 1 year, even with improved follow-up and
stricter definitions of failure. In patients with large left atria, there might be a need for more extensive size
reduction or expanded lesion sets. (J Thorac Cardiovasc Surg 2011;141:113-21)The Cox maze procedure was introduced in 1987 at our in-
stitution for the treatment of atrial fibrillation (AF) by
Dr James L. Cox.1 The first 2 iterations of this procedure
were abandoned because of a high incidence of pacemaker
implantation and technical difficulty. The final version in-
troduced was the Cox maze III procedure, and it remained
the gold standard for the treatment of AF for more than a de-
cade. In a follow-up study of 198 consecutive patients from
our institution, the overall freedom from symptomatic
AF was 97% with a mean follow-up of 5.4  2.9 years.2
Although this was a high success rate, the patients did not
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The Journal of Thoracic and Cathe rhythms were documented only by means of a mailed
questionnaire or telephone interview. Very few of the pa-
tients had any monitoring more than an electrocardiogram
to document their rhythm. Moreover, the most recent
consensus statement on ablation for AF has proposed that
success be defined as freedom from AF, atrial tachycardia,
or atrial flutter (atrial tachyarrhythmias [ATAs]) off of anti-
arrhythmic drugs.3 In our previous report success was con-
sidered simply freedom from symptomatic AF. Our results
with the original cohort of the cut-and-sew Cox maze III
procedure showed that 27% of patients were taking antiar-
rhythmic drugs at the last follow-up.2
In 2002, a new iteration of the Cox maze procedure was
introduced, termed the Cox maze IV procedure, which
replaced most of the incisions with linear lines of bipolar ra-
diofrequency ablation (Figure 1).4 Initially, the procedure
had only a single inferior connecting ablation line between
the pulmonary veins in an attempt to better preserve left
atrial function. However, a second connecting lesion supe-
riorly was added several years later to anatomically isolate
the entire posterior left atrium (termed the box lesion set) in
an attempt to improve early and late results. At this time, we
also adopted a more rigorous follow-up of the patients, with
all patients having either electrocardiographic or 24-hour
Holter monitoring at 3, 6, and 12 months and annually
thereafter. An examination of predictors of failure after
the Cox maze procedure was published by our group inrdiovascular Surgery c Volume 141, Number 1 113
Abbreviations and Acronyms
AF ¼ atrial fibrillation
ATA ¼ atrial tachyarrhythmia
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D2005.5 However, the great majority of patients in this series
underwent a Cox maze III procedure. As stated above, the
definition of failure was not rigorous, and patients rarely
had electrocardiographic monitoring. The only risk factors
for late recurrence of AF were duration of preoperative AF
and earlier version of the Cox maze procedure, with both
the Cox maze I and II procedures having higher failure rates
than the Cox maze III procedure.
To better define predictors of failure in the modern era,
this study was designed to look at our experience with the
Cox maze IV procedure alone, in which follow-up has
been more rigorous and intensive, with 24-hour Holter
monitoring obtained in the majority of patients at 3, 6,
and 12 months. Moreover, success was defined only as pa-
tients being both free of ATAs and off antiarrhythmic drugs.
A previous report from our institution has shown that this is
important to accurately define criteria for successful out-
come.6 In this study our prospective database was reviewed
to evaluate the predictors of late ATA recurrence in 282 con-
secutive patients who underwent a Cox maze IV procedure.MATERIALS AND METHODS
From January 2002 through December 2009, 282 patients underwent
a Cox maze IV procedure for AF. All procedures were performed during
cardiopulmonary bypass. The right atrial lesion set was done on the beating
heart, whereas the left atrial lesions were performed during cardioplegic ar-
rest. As described previously, 2 small atriotomies were performed. The rest
of the incisions of the Cox maze III procedure were replaced with linear
ablation lines by using either the AtriCure (West Chester, Ohio) or Med-
tronic (Minneapolis, Minn) bipolar radiofrequency clamp. At the tricuspid
and mitral valve annuli, cryoablation was used in the vast majority of cases.
In a small number of cases, a unipolar ablation pen, either the AtriCure
Max1 or the Medtronic Cardioblate XL pen, was used. The coronary sinus
was ablated both with the bipolar clamp and with epicardial cryoablation.
In 245 (87%) patients electrical pulmonary vein isolation was con-
firmed by pacing, demonstrating exit block from each of the pulmonary
veins. Of the 37 patients who did not have pacing thresholds or exit block
checked, 12 patients had a suspicious left atrial appendage clot seen, and
cardioversion could not be performed. Thirteen patients remained in AF
despite cardioversion or were in heart block. Initially, we only performed
a single inferior connecting lesion between the pulmonary veins, leaving
most of the posterior left atrium in electrical continuity with the remainder
of the atrial myocardium. In 2005, a second superior connecting lesion was
added (the box lesion set) to anatomically isolate the entire posterior left
atrium (Figure 1). Pacing was not performed to confirm the electrical iso-
lation of the posterior left atrium. Although the majority of patients under-
went their procedures through a median sternotomy, 29 had a less-invasive
right minithoracotomy approach. These patients had an identical lesion set
that has been previously described.7 However, the left atrial appendagewas
oversewn from the endocardial surface instead of being amputated. Of the
entire group, 95 (34%) patients underwent a stand-alone maze procedure.
The majority underwent concomitant surgical procedures, with the most114 The Journal of Thoracic and Cardiovascular Surgcommon being either a mitral valve procedure or coronary artery bypass
grafting (Table 1). AF was defined as paroxysmal, persistent, or long-
standing persistent per recent guidelines.3 The patients’ clinical profiles
and postoperative outcomes were recorded prospectively in a longitudinal
database containing 386 variables. All patients were available for follow-
up, and every patient had a minimum 3-month follow-up.
In this series patients were started on class I or III antiarrhythmic drugs
and warfarin before hospital discharge. If they were in sinus rhythm at
2 months, the antiarrhythmic drugs were discontinued. At 3 months,
24-hour Holter monitoring and echocardiography were performed. If
patients had no evidence of ATAs or atrial stasis by means of echocardiog-
raphy, their anticoagulation was stopped.
Follow-upwas conductedbyobtainingelectrocardiograms for all patients
at 3, 6, and 12months. Since 2006, when the new guidelines were first circu-
lated, 24-hourHoltermonitoring or pacemaker interrogationwas obtained in
94%of patients.Late recurrencewas defined as any episodeofAF, atrial flut-
ter, or atrial tachycardia that lastedmore than 30 seconds. Any patient requir-
ing an interventional procedure after 3 months was deemed a permanent
failure. Patients were only considered to be a success if they were both off
antiarrhythmic drugs and free of ATAs. For the purpose of this analysis,
we defined antiarrhythmic drugs as either Vaughan–Williams type I or III.
b-Blockers or calcium-channel blockers were not considered to be antiar-
rhythmic drugs. Only patients who were alive at 12 months were included
in the analysis. This study was approved by the Washington University
School of Medicine Institutional Review Board. Informed consent and
permission for release of information were obtained from each participant.
Continuous variables are expressed as means standard deviations un-
less otherwise specified, and categorical data are expressed as counts and
proportions. Comparisons were done with paired, 2-tailed t tests for means
of normally distributed continuous variables. Either the c2 or Fisher’s exact
test was used to compare categoric data. Thirteen preoperative and perio-
perative variables were evaluated in a univariate analysis to identify poten-
tial predictors of late ATA recurrence. These included age, sex, type and
duration of AF, NewYork Heart Association class, type of bipolar radiofre-
quency device, left ventricular ejection fraction, failed catheter ablation,
left atrial diameter, pulmonary vein box versus nonbox lesion set, concom-
itant versus stand-alone Cox maze procedure, early ATAs (within the first
postoperative month), and early postoperative pacemaker implantation
within the first 90 days. Significant covariates on univariate analysis
(P  .10) or covariates deemed clinically relevant based on our experience
were entered into a multivariate binary logistic regression analysis. All data
analyses were performed with SPSS software (SPSS 11.0 for Windows;
SPSS, Inc, Chicago, Ill).
RESULTS
Demographics
The mean age of patients undergoing a Cox maze IV pro-
cedure was 63  12 years (range, 23–83 years; Table 2).
There were 177 men and 105 women. Forty-two percent
of patients were in paroxysmal AF. Ten percent were in per-
sistent and 48% were in long-standing persistent AF. The
median duration of AF was 3.7 years. Most patients
(66%) underwent concomitant cardiac operations. Among
patients undergoing a stand-alone Cox maze procedure,
46% (n ¼ 44) were referred for failure of medical therapy,
40% (n ¼ 38) had catheter ablation failure, and 14%
(n ¼ 13) were referred for either a stroke or transient ische-
mic attack. In the entire series 52 (18%) patients had previ-
ous catheter ablation failure.
In the concomitant group half of the patients underwent
mitral or mitral plus tricuspid valve surgery (93 [50%]ery c January 2011
FIGURE 1. A, Right atrial lesion set of the Cox maze IV procedure. B, Left atrial lesion set of the Cox maze IV procedure.
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bypass grafting with or without mitral valve repair. In 29
(16%) patients the primary indication was for aortic valve
replacement. The rest of the patients underwent more com-
plicated concomitant procedures (Table 1).
Perioperative Results
The overall operative mortality was 2% in the entire
series and 1% in the stand-alone Cox maze cohort. The
mean aortic crossclamp time for patients undergoing
a Cox maze procedure with concomitant surgical interven-The Journal of Thoracic and Cation was 96  27 minutes. This was shorter in patients un-
dergoing a lone Cox maze procedure (43  15 minutes).
Previous published work from our group has shown that
these times were significantly shorter when compared
with our experience with the traditional cut-and-sew Cox
maze III procedure.8 The median length of stay was 9
days (range, 4–73 days). Eleven percent of patients had
major perioperative complications (n ¼ 31). These compli-
cations include reoperation for bleeding (n ¼ 14), intra-
aortic balloon pump placement (n¼ 9), stroke (n¼ 5), renal
failure (n ¼ 12), and mediastinitis (n ¼ 1). Seven patientsrdiovascular Surgery c Volume 141, Number 1 115
TABLE 1. Concomitant cardiac procedures (n ¼ 187)
No. %
CMþmitral valve procedure 79 42
CMþmitral valveþ tricuspid procedure 14 7
CMþCABG 26 14
CMþCABGþmitral valve procedure 17 9
CMþaortic valve procedure 16 9
CMþaortic valveþCABG 13 7
CMþmitral valveþaortic valve procedure 5 3
CMþseptal myectomy  additional procedures 7 4
CMþother procedures 10 5
CM, Cox maze procedure; CABG, coronary artery bypass grafting.
FIGURE 2. Freedom from atrial tachyarrhythmias (ATAs) with and with-
out antiarrhythmic drugs at 3, 6, and 12 months with number of patients at
risk.
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Early postoperative atrial arrhythmias were documented in
53% of patients (n ¼ 150). These dysrhythmias were usu-
ally transient, and most resolved over the first month. Early
permanent pacemaker placement within 30 days of the op-
eration occurred in 9% (n ¼ 24) of patients. A large major-
ity of these patients had documented evidence of sick sinus
syndrome preoperatively.Late Follow-up
Follow-up was available in all patients. After a Cox maze
IV procedure, the freedom from ATAs was 89%, 93%, and
89% at 3, 6, and 12 months, respectively (Figure 2). TheTABLE 2. Patients’ characteristics
Variables
Stand-alone
CM (n ¼ 95)
Concomitant
CM (n ¼ 187)
No.
% or
(range) No.
% or
(range)
Preoperative
Age (y) 56  10 28–77 66  12 23–83
Male sex 73 77 104 56
AF duration (y)
Mean 7.5  6.7 0.1 –28.0 5.8  7.9 0.1–46.0
Median 6.0 3.0
Paroxysmal AF 29 31 89 48
NYHA class 3 or 4 19 20 141 75
Sleep apnea 18 19 30 16
History of failed
catheter ablation
38 40 14 7
Operative
Mean CCT (min) 43  15 96  27
Box lesion around PVs 73 77 151 81
LA diameter (cm) 4.8  1.1 2.5–8.0 5.5  1.2 2.9–10.0
Postoperative
Operative mortality
(30 d)
1 1 6 3
Early ATA 42 44 108 58
Median hospital LOS (d) 7 4–53 10 4–73
Values are presented as number or percentages (ranges). CM, Cox maze procedure;
AF, atrial fibrillation; NYHA, New York Heart Association; CCT, aortic crossclamp
time; PVs, pulmonary veins; LA, left atrium; ATA, atrial tachyarrhythmias (including
AF, atrial tachycardia, and atrial flutter); LOS, length of stay.
116 The Journal of Thoracic and Cardiovascular Surgfreedom from both antiarrhythmic drugs and arrhythmias
was 63%, 79%, and 78% as 3, 6, and 12 months, respec-
tively. Of the 70% (n ¼ 178) with prolonged monitoring,
92% (n ¼ 164) were free of ATAs and 79% (n ¼ 141)
were free of ATAs and off antiarrhythmic medications.
There was no difference in the late success rate for patients
with paroxysmal versus persistent or long-standing AF
(P ¼ .378). There also was no difference in success rates
for patients undergoing stand-alone versus concomitant
procedures (P ¼ .361). Of the 16 patients with ATAs at 6
months, 9 patients had recurrent AF, 5 patients had atrial
flutter, and 1 patient had atrial tachycardia. At 12 months,
15 patients had recurrent AF, and 5 patients had atrial flutter.Recurrence of ATAs
A univariate analysis of preoperative and perioperative
variables was performed to determine potential predictors
of late ATA recurrence. The only significant predictors of
recurrence on univariate analysis were the absence of
a box lesion set, increasing left atrial diameter, and early
postoperative ATAs. The following variables were entered
into a multivariate logistic regression to determine risk fac-
tors for failure after a Cox maze procedure: age, AF dura-
tion, box versus nonbox lesion set, left atrial diameter,
early postoperative ATAs, and early pacemaker implanta-
tion. Left atrial size was a significant predictor of failure,
with an odds ratio of 1.42 (Table 3). The probability of
AF recurrence increased with increasing left atrial diameter
(Figure 3). The failure to anatomically isolate the entire
posterior left atrium (nonbox lesion set) was also predictive
of failure with a P valve of .022. Finally, patients with early
postoperative ATAs were significantly more likely to fail,
with an odds ratio of 3.05. As opposed to our prior publica-
tion, duration of preoperative AF was not a predictor of fail-
ure. Other variables that were not predictors of failure at 12
months by means of multivariate analysis included age and
early pacemaker implantation.ery c January 2011
TABLE 3. Multivariate logistic regression analysis of risk factors for
failure after the Cox maze IV procedure (38/187 [20.3%])
Variable No. Odds ratio 95% CI P value
Left atrial diameter 187 1.420 1.04–1.94 .027
Box lesion set around
pulmonary veins
137 0.382 0.167–0.871 .022
Early atrial tachyarrhythmias 96 3.020 1.079–8.455 .010
CI, Confidence interval.
Left Atrial Size (cm)
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40
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FIGURE 3. Relationship between left atrial size and probability of atrial
fibrillation (Pr [AF]) recurrence.
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DDISCUSSION
The Cox maze procedure has been the most successful
surgical treatment for AF.2,9-11 Our institution has had the
longest experience with this operation and has maintained
a prospective database over the last 2 decades following
all of our patients. Although we have published
extensively on our series, our prior reports have generally
not followed recent guidelines in terms of recommended
follow-up or definition of failure.3 In this report of more
than 280 patients, follow-up was more rigorously collected,
with a strict definition of AF recurrence consistent with the
recent consensus statement. Moreover, this report only in-
cluded patients undergoing an ablation-assisted Cox maze
IV procedure. This is more relevant to modern practice be-
cause we have not performed a cut-and-sewmaze procedure
in 8 years. Furthermore, with the more rigorous follow-up
and definition of failure, the present study provides
a much more accurate representation of late recurrence,
allowing for a better elucidation of preoperative and postop-
erative risk factors leading to failure of the Cox maze
procedure.
In this case series the Cox maze procedure had excellent
results at 1 year, with 89% of patients free from atrial dys-
rhythmias and 78% free of arrhythmias and off drugs. In pa-
tients undergoing a stand-alone procedure, the success rates
were 91% and 74%, respectively. This compares favorably
with our historical data from the Cox maze III procedure, in
which only symptomatic follow-up was obtained.2 In our
previous report 80% of patients undergoing a stand-alone
procedure were both free of AF and antiarrhythmic drugs
at last follow-up. In the concomitant group 73% of patients
were in sinus rhythm and off antiarrhythmic drugs at last
follow-up. Although follow-up in our previous report was
longer, virtually none of these patients had electrocardio-
graphic or Holter monitoring to determine their actual heart
rhythm. It is heartening to see similar numbers obtained
with more aggressive follow-up and a stricter definition of
recurrent ATAs. It also is important to remember that in
the current era, we are operating on a sicker cohort of pa-
tients with higher incidences of congestive heart failure
and other comorbidities who undergo more complex
concomitant operations. Because of the difficulty and
time-consuming nature of the traditional cut-and-sew Cox
maze III procedure, principally low-risk patients were
historically offered concomitant surgery.The Journal of Thoracic and CaThere were 3 risk factors for recurrent atrial arrhythmias
after the Cox maze IV procedure using our multivariate lo-
gistic regression analysis. These included left atrial size,
failure to anatomically isolate the entire posterior left
atrium, and early ATAs (Table 3). Increasing left atrial
size was a significant risk factor for failure (Figure 2).
This agrees with previous reports in the literature.12-14
This is not surprising because our laboratory has shown
that as atrial surface area increases, there is a higher
incidence of inducible AF.15 In this study the probability
of recurrent tachyarrhythmias exceeded 50% once left
atrial size was greater than 8 cm. Although it has been our
policy to perform a left atrial reduction in left atria of
7 cm or larger, this added procedure obviously was not suc-
cessful in preventing recurrence. Patients with large left at-
ria need to be adequately counseled on their high risk for
failure. In this group the value of concomitant AF ablation
remains unclear, and surgeons should be cautious adding
the Cox maze procedure if there is any chance that it might
increase perioperative risk. Our data do suggest the need for
either a more aggressive left atrial reduction or a more
extensive ablation lesion set in this patient population.
Another risk factor for recurrence of ATAswas the failure
to anatomically isolate the entire posterior left atrium. Our
initial version of the Cox maze procedure involved only 1
inferior connecting lesion between the pulmonary vein
isolations, thus leaving most of the posterior left atrium in
continuity with the rest of the left atrium.4 In 2005, we be-
gan to isolate the entire posterior left atrium by making 2
connecting lesions, one between the left and right inferior
pulmonary veins and one between the superior pulmonary
veins. This significantly increased our drug-free success
rates in a prior report.6 In this larger series of patients,
this still remained a significant risk factor for recurrence.
It is our present recommendation that all patients undergo-
ing surgical ablation for AF have their entire posterior left
atrium anatomically isolated. This finding in surgicalrdiovascular Surgery c Volume 141, Number 1 117
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tory, in which wide-area circumferential ablation involving
most of the posterior left atrium has been shown to be more
effective than targeting only the pulmonary veins.3,16,17
A final risk factor for failure was patients who experi-
enced early tachyarrhythmias. This does not agree with
a prior report from our group, but it is intuitive that these pa-
tients would have a higher failure rate.18 Early ATAs were
managed aggressively, first with chemical and then electri-
cal cardioversion if drug therapy was unsuccessful. Cardio-
version was usually performed between 1 and 4 weeks
postoperatively. The high incidence of early ATAs in this
group is likely due to a number of reasons. All of the pa-
tients had preoperative AF, usually of long duration, and
had already developed the appropriate substrate required
to sustain this arrhythmia. Also, previous work from our
laboratory has shown that early postoperative AF is due to
myocardial inflammation.19 The multiple atrial ablations
likely cause a robust inflammatory response. It is not known
whether a more aggressive attempt to prevent early ATAs
would improve late success, but this seems unlikely. It is
more probable that early ATAs might be a marker of
a more advanced pathology of the atrial substrate, and this
would logically make these patients more prone to late
recurrence.
Numerous factors were not found to be associated with
late failure on univariate analysis, including sex, age, New
York Heart Association class, type of bipolar device, type
or duration of AF, ejection fraction, failed catheter ablation,
or postoperative pacemaker implantation. It is interesting
that in this study preoperative AF duration was not shown
to be a significant predictor of late failure. This contradicts
our prior report evaluating mainly the Cox maze III proce-
dure.5 This might be a result of patients being referred ear-
lier for AF ablation, as indicated by a significantly lower
median duration of AF in this series (3.7 years) compared
with our previous report (5 years). It might be also due to
the fact that in patients with concomitant structural heart
disease, who comprised 66% of the patients in this series
but only 41% of patients in our prior report, the effect of
prolonged duration of AF is overwhelmed by the electrical
remodeling and atrial dilatation caused by congestive heart
failure and valvular heart disease.5
The study has several limitations. Although follow-up
has improved considerably over time, there are still patients
who did not have 24-hour Holter monitoring, and thus the
actual failure rate might be underestimated.20 However,
compared with previous reports in the literature, this patient
cohort has been well monitored, and no patient was lost to
follow-up. Another limitation of this report was that the pre-
cise mechanism of ATA recurrence was not defined in the
majority of patients. The question remains unanswered
whether this was due to technical difficulty in performing
a complete Cox maze lesion set or to inherent atrial pathol-118 The Journal of Thoracic and Cardiovascular Surgogy. Because we have been performing this procedure for
more than 2 decades, it is unlikely that the failures were
due to an inappropriately performed lesion set. It is possible
that there were recurrences due to bridging of cardiac con-
duction over the linear scars formed by the bipolar devices,
but this phenomenon has not been demonstrated in patients.
It also is possible that some of the lines of ablation were not
actually transmural because only the efficacy of pulmonary
vein isolation was tested. In the future, our hope is to per-
form noninvasive electrocardiographic imaging to better
define the mechanisms of failure and allow us to develop
strategies to improve surgical success rates.
In conclusion, failure to isolate the entire posterior left
atrium and increasing left atrial diameter were the 2 risk
factors for failure that can be modified by surgeons. In
patients with a large left atrium, this study would suggest
that efforts to improve left atrial reduction procedures or
perform more extensive lesion sets are warranted.References
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DDiscussion
Dr Michael Argenziano (New York, NY).My disclosure is that
I am a consultant for Estech.
Ralph, you and your group need to be congratulated for another
outstanding presentation in the area of atrial fibrillation, and you
have certainly carried on Dr Cox’s tradition at St. Louis very
well. Thank you for the manuscript in advance, as that was obvi-
ously very helpful.
As you noted, the Cox maze procedure was really the gold stan-
dard and really remains the gold standard for the treatment of atrial
fibrillation; however, it was never adopted in any sorts of great
numbers because of its complexity. As you know, since the late
1990s, a number of more ‘‘limited’’ procedures using a variety
of energy sources have been developed and, unfortunately, there
have been many energy sources, many lesion sets, many selection
criteria, andmany definitions of success, et cetera, to the point that,
although we have been doing this for over 10 years, many ques-
tions remain. Those are, what are the best energy sources? Are
there certain energy sources that are better in certain applications
than others? What are the better lesion sets? Should we be using
a box versus an isolated pulmonary vein approach? Should we
be doing left atrium only or both atria, as you did here? How do
we select patients? And then, most importantly, I believe, how
do we follow these patients up? Because although you did a tre-
mendous job in following up these patients, the total percentage
of the time that these patients are alive that you have monitored
is really very small, and especially because you have such a high
paroxsymal A-fib component, how dowe knowwhat these patients
are doing when they are not being monitored?
Your findings in a large group of patients with atrial fibrillation,
which were a mix of both paroxsymal and nonparoxysmal patients
but which were mostly condominant, were that a box lesion is bet-
ter, and I certainly would agree with that, and we have been saying
for years and many of us have been saying that a box lesion just
electrophysiologically makes more sense, because not only does
it eliminate the triggers of atrial fibrillation that occur within the
pulmonary veins but it also acts to compartmentalize the left
atrium and reduce the ability of the substrate to contribute, as
Dr Cox taught us.
You found that a large left atrium is worse, and we concur with
that and we have actually published that as well, and it makes good
sense that probably the best surrogate of the degree of remodeling
that exists in an atrium is not duration or anything else or age but
rather the size of the atrium.The Journal of Thoracic and CaAnd then, finally, you found that early arrhythmias predicted
a worse outcome, which actually was a surprise to us, because
we looked at this as well and we actually have found that there
is no difference and, for that reason, have not really been very
aggressive about managing the early arrhythmias, although I
would like to hear more from you about that.
So, you had excellent overall success. You used right-sided
lesions universally, which we would agree with, and, again, you
had excellent follow-up. I have 3 questions for you.
First is, you have shown that the box lesion is better, but we know
that the majority of the patients that you operated on in this series
were concomitant, although a third were stand-alone procedures.
You and I have spoken before, and I know that you have done
many more than 95 stand-alone atrial fibrillation ablations. So,
therefore, you must be doing some of the standalone patients with
lone atrial fibrillation with a purely epicardial pulmonary vein bipo-
lar clamp technique. If so, how did you choose those patients and
why did the patients in this series get a more extensive lesion set?
Dr Damiano. That is an excellent question. Just to be as quick
as possible, we have done a significant number of the epicardial
approaches. We favor the bipolar clamps, and that has been most
of our experience. We initially performed the procedure on
a wide group of patients, though we have had, like others, poor re-
sults in patients with persistent or long-standing atrial fibrillation.
We are no longer offering this operation to this group because of
the poor results. And, to be honest with you, we cannot find any
device in our research laboratory capable of making reliable linear
lesions on the beating heart. I do not think there is one on the mar-
ket right now. However, we are initiating some hybrid approaches
with our electrophysiologists to help us overcome some of these
shortcomings. At present, we would consider patients with parox-
ysmal atrial fibrillation and a left atrial diameter of less than 5 cm
as good candidates for pulmonary vein isolation done thoraco-
scopically or with small incisions. Our success rates have not
been quite as high as with a full Maze procedure. The last time
we looked, it was about 75%. This is not bad, and you could
view it as part of a staged procedure. So we do offer that.
We give our patients full informed consent. We let them look at
our published results and our database results and let them choose
between the procedures. As we both know, some patients go for
a minimally invasive approach and some patients, particiularly if
they have failed a number of catheter ablations, just want to be
cured and they will go for a more complete procedure. You can
do the full maze IV, similar to our previous discussion, through
a right minithoracotomy. It is a lot easier than doing mitral valve
repair and with present devices it can be done very well. I agree,
you have to tailor your procedure to each specific patient.
I would caution those people who are doing epicardial pulmo-
nary vein isolation as their only procedure for atrial fibrillation
to be very careful that the patient’s arrhythmia is not actually atrial
flutter. This is quite common in failed catheter ablations, which
now make up over half of our stand-alone experience. You should
study them or make sure you have a qualified physician review
their EKGs and Holter monitors. Because if they have recurrent
flutter, which is not unusual, the only operation you can do is
a complete Maze procedure.
DrArgenziano. I would agreewith that. And, in fact, at Colum-
biawe have for at least a few years now actually not offered a purelyrdiovascular Surgery c Volume 141, Number 1 119
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Depicardial operation to patients with either multiple failed abla-
tions, enlarged atria, poor ejection fraction, and we reserve that
really to the purely early paroxsymal patients, which, unfortu-
nately, are exceedingly fewer and fewer because of the success
of catheter ablation.
Two brief questions. If earlier tachyrhythmias in the periopera-
tive period are a predictor of failure, what are you doing to either
treat that or to study those patients? In other words, do you think
that early arrhythmias predict failure because atrial fibrillation in
the perioperative period begets atrial fibrillation or do you think
that early atrial fibrillation is simply a surrogate for incomplete le-
sions?
Dr Damiano. That is an excellent question, Mike, and I can’t
really answer it. As you know, we published in Circulation in
2005 our maze III experience in which early arrhythmias were
not a predictor of late failure. It has turned out to be a predictor
in this study, and the only thing I can tell you is we now have
a much stricter definition of failure in that any patients who were
on antiarrhythmic drugs were considered a failure. So we have es-
tablished a more strict definition and perhaps that is allowing us
some more discriminatory ability.
My own feeling is it is not an incomplete lesion set, and we, like I
am sure you do, test for conduction block. The pulmonary vein
isolation is tested in every patient we are able cardiovert, which is
over 90% of this patient cohort. I think that early arrhythmias are
a marker of a worse atrial substrate, probably increased atrial fibro-
sis.We are doing a lot sicker patients and, like you say, I completely
agree, left atrial diameter is a really good surrogate for atrial remod-
eling. As I have thought about this more, I am not even sure that
being aggressive with atrial reduction will be enough in some of
these patients. There is a group of patients that I am convinced
we shouldn’t probably be operating on because of end-stage atrial
myopathy. In terms of restoring sinus rhythm, we are pretty aggres-
sive. We usually delay early cardioversion, but at 1 month we ag-
gressively attempt to restore sinus rhythm in all of those patients.
Dr Argenziano. The last question is about follow-up, and that
really I think winds up being the most interesting part of this entire
area. As you know, the Cardiothoracic Surgery Trials Network,
which is an NIH network grant, is currently involved in a random-
ized study looking at atrial fibrillation ablation, and one of our
main interests in that trial is really to figure out how can we im-
prove the way that we follow up these patients. How can we calcu-
late not just things like incremental A-fib incidents but rather
things like atrial fibrillation burden? And so what do you think
about implantable devices and transtelephonic monitoring and
ways to even increase even the excellent follow-up that you have?
Dr Damiano. I think that is an excellent point and a relatively
unanswered question. We have looked at our data and when we
eliminated the patients who just had ECG follow-up, it did not im-
pact the success rate. Unfortunately, the ECG follow-up group was
generally in the early part of our series when we did the nonbox
lesion, so it may have confounded the analysis.
I agree with you, monitoring remains a big question mark. I do
feel an EKG alone is not adequate in 2010. We are presently start-
ing a clinical trial with the Reveal device by Medtronic, which is
an implantable device, which would allow you almost continuous
monitoring. The question is how valuable this is going to be. What
if a patient has a minute of atrial fibrillation in a month? What120 The Journal of Thoracic and Cardiovascular Surgshould we do about that? I think it is going to make management
interesting.
I think that is something that I hope the NIH trial answers and,
as we gain more experience with these new implantable devices,
we may be able to understand exactly what the right thing to do is.
Dr Argenziano. Congratulations on a great study, Ralph.
Dr Richard Shemin (Los Angeles, Calif). Another major con-
tribution to the outcomes and work that you have done at Wash U
for A-fib. Obviously, we all agree that transmurality is important. I
think you just mentioned that in over 90% of the cases you do intra-
operative testing.
A technical question: How many times do you have to reapply
the clamp a second or a third time?
DrDamiano.Wewere one of the first groups to put out aword of
caution that we occasionally required 8 or 9 clamp applications to
isolate the pulmonary veins with the early versions of some of these
bipolar devices. With the 2 present versions, the Medtronic Cardio-
blate and the AtriCure Synergy clamps we found, that both have
excellent results. In general, I would say that they are over 90% ef-
fective with a single ablation when judged by the creation of con-
duction block. We are in a clinical trial with 1 of the devices
where we are testing this question. While I haven’t seen the multi-
center data, our own data has shown an over 95% success rate in cre-
ating conduction block with a single ablation, but it is not 100%.We
do 2 ablations for every lesion and then test by pacing from each
pulmonary vein. One of the reasons we don’t have data in all
patients for exit and entrance block is that we have a number of pa-
tients who either have a left atrial thrombus, which I would not rec-
ommend cardioversion because of the potential for emboli, or in
whom we are unable to restore sinus rhythm with cardioversion.
Dr Shemin. Since early recurrence of atrial fibrillation or other
arrhythmias is an adverse predictor, what is your specific postop-
erative protocol as far as antiarrhythmic drugs and early cardiover-
sion?
Dr Damiano.We have not changed any of our protocols based
on the results of this study, at least at the present time. Every pa-
tient that comes out of surgery, once they restore their sinus rhythm
is started on antiarrhythmic drug. Our drug of choice is amiodar-
one or whatever drug they tolerated preoperatively, and we
continue that for 2 months.
We have been aggressive with cardioversion, but ideally we
usually delay cardioversion for 3 to 4 weeks to let all the inflam-
mation subside.We found, as opposed to postoperative atrial fibril-
lation in patients undergoing CABG for instance, a lot of these
patients do not respond to early cardioversion. If it is not success-
ful, it can be upsetting to the patient.
When we see the patients back in a month, if they are in an atrial
flutter or fibrillation we will arrange cardioversion. I arrange it
myself. I don’t leave it up to the referring cardiologist.
Dr Shemin. Final question: Is there any role for the Cox maze
III procedure?
Dr Damiano. We talked about that in the panel, and at our in-
stitution right now, no, I don’t see any role for it.
Dr Thorsten Hanke (Luebeck, Germany). Congratulations on
your results. Just one question. Your more intensified monitoring,
that was about 25% of the patients?
Dr Damiano. Seventy percent of the entire population had ei-
ther 24-hour Holters or more prolonged monitoring. After 2006,ery c January 2011
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prolonged monitoring.
Asmanyof youknow, if you follow large numbers of patientswith
atrial fibrillation, it is hard enough to get them to comeback. It can be
harder and harder as you try to get longer periods ofmonitoring. But,
yes, the majority of patients here had prolonged monitoring.
Dr Hanke. Did you see any difference with your more
prolonged observations than with the short-term ones? And keep
in mind that, even with a 14-day Holter strategy, you only have
a sensitivity of about 69 to 70%. So don’t you think it is time for
continuous monitoring, never mind whether it is Medtronic, Bio-
tronic, whatsoever, for all the patients?
Dr Damiano. I think it is an excellent point and to truly define
failure rates we will need to use such devices. But, as you know,
certainly at least in the United States, there have not been small im-
plantable devices available until recently and the reimbursement
has been a problem. So it has not been a viable option. But I agree,
and we will learn a lot from continuous monitoring.
However, as I said in my previous comment, if you took out
from our series the patients who had ECG only, using prolonged
monitoring did not result in a significant change in our failure
rate. However, I totally agree with you, and there are certainly
a number of studies in the electrophysiology literature and a few
from our literature that would suggest that, the more you monitor,
the more arrhythmias you will discover.
I will just put a note of caution for those of you who follow these
patients. We are following over 500 to 600 patients right now, and
what we would do with continuous monitoring in 500 patients. An
army of people would need to deal with all this data. There may
be medicolegal issues if, for instance, a patient had a 1-minute epi-
sode of atrial fibrrillation andwedidn’t do anything butwehappen to
have the electrograms stored in some computer warehouse. It is not
a trivial process.We arewrestling with what we are going to dowith
this mountain of data. We will need some help with it. But I totally
agree with your point there, and I think it will be an advance.
Dr Masashi Komeda (Kyoto, Japan). Congratulations on
a beautiful study. As you mentioned, left atrial diameter is so
important. We did a study of atrial reduction, Cox maze III proce-The Journal of Thoracic and Cadure, and we published the data from JTCVS twice. When we did
a volume reduction one third as big as before the surgery, the
defibrillation rate was quite high. I want to share your comment
on that.
Dr Damiano. I am aware of your excellent work and certainly
in my conclusions mention that we need to maybe adapt a more
aggressive atrial reduction procedure in patients with large left
atria to improve our success rates. We also may need a more
extended lesion set.
I will tell you, there is a subset of those patients that probably no
matter what you do, you won’t be able to cure them. They have
remodeled their atrium and they are so fibrotic that really no
amount of reduction will work. DrMadison Spach at Duke showed
that in elderly patients with atrial fibrosis that they can maintain
atrial fibrillation in a single trabeculae crossing the right atrium.
These patients we shouldn’t operate on, and perhaps MRI or
body surface mapping may help us identify this substrate before
the operation. But I acknowledge your work, and we are going
to try a little more aggressive reduction procedure in the future,
similar to what you have published.
Dr Komeda. Thank you. About that issue, maybe you are right
for some patients, but for some others, interestingly, the left atrium
keeps shrinking 1 year after surgery; it just keeps shrinking. So
maybe some patients still have a chance to have that type of reverse
remodeling and a better outcome of defibrillation.
Dr Damiano. I agree with you. It is trying to discriminate who
is going to get better and who isn’t. That would be very helpful be-
fore we put them through this surgery.
DrMarco Zenati (Pittsburgh, Pa). I enjoyed your presentation
and congratulations, especially for bravely adopting the guidelines
for both efficacy and follow-up. My question about the intensity of
the follow-up was already answered. I just want to make a brief
comment about the fact that your outcomes are based on a single
procedure and, if the guidelines were meant to compare surgical
versus catheter ablations, it is important that we compare single
procedures to single procedures.
Dr Damiano. I agree completely, but you need to be talking to
electrophysiologists, not me. They never like to do that.rdiovascular Surgery c Volume 141, Number 1 121
